Effect of methylphenidate on fatigue in women with recurrent gynecologic cancer

Johnson, Rhonda L.; Block, I.; Gold, Michael A.; Markwell, Stephen; Zupancic, Melanie

doi:10.1002/pon.1646

Cited by 21 publications

(18 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Depression in cancer patients may also come with tiredness. In regard to treatment of cancer-related fatigue, methylphenidate has long been studied to be very effective, despite its side effects [9,53]. Modafinil was also well-tolerated and effective against fatigue in cancer patients when self-administrated for four weeks [10].…”

Section: Application For the Countermeasure Of Fatiguementioning

confidence: 99%

Practical Use and Risk of Modafinil, a Novel Waking Drug

Kim

2012

Environ Health Toxicol

View full text Add to dashboard Cite

ObjectivesModafinil is a waking drug prescribed to narcolepsy patients, but its usage among healthy individuals is increasing to enhance their alertness or to mitigate fatigue. This study was conducted to investigate practical use and toxic effects on neuro-immune interaction of modafinil.MethodsThis study reviewed the significance of psychoactive drugs, and discussed the benefits and risks of the application of modafinil, which seems to be ideal as an anti-psychotic or anti-fatigue agent.ResultsModafinil is known to have less or no adverse effects than those found in traditional psychostimulants such as amphetamine, methylphenidate or cocaine. It can be applied as an anti-psychotic or anti-fatigue agent. However, the waking mechanism of modafinil is yet to be fully revealed. Recent studies reported that modafinil may be subject to abuse and addiction. In addition prolonged sleeplessness induces stress responses and impairs immune function.ConclusionsModafinil can be used by anyone, who wishes to work late, stay awake, enhance their cognitive reactions, or brighten their moods. Users may already be under a great level of stress, i.e. cancer patients or soldiers in a battle field. A psychoneuroimmunological approach is thus needed to investigate the multi-functional effects of modafinil.

show abstract

Section: Application For the Countermeasure Of Fatiguementioning

confidence: 99%

Practical Use and Risk of Modafinil, a Novel Waking Drug

Kim

2012

Environ Health Toxicol

View full text Add to dashboard Cite

show abstract

“…Most drugs were not compared with placebo or did not show significant benefit compared with placebo (Fig. 3) [7,8,[103][104][105][106][107][108][109][110][111][112][113][114][115][116][117][118]. One drug, methylphenidate, showed promising results [111][112][113]119], but in the latest and largest trials, no improvement of fatigue by this treatment was found compared with placebo [114,120,121].…”

Section: Pharmacological Treatmentmentioning

confidence: 99%

“…Details and results of this search can be found in supplemental online Appendix 2. Drugs that were studied for their effect on CRF were bupropion [103] [110], methylphenidate [15,[111][112][113][114][115]120], modafinil [2,116], paroxetine [7,8], and thyrotropin-releasing hormone [117]. Most drugs were not compared with placebo or did not show significant benefit compared with placebo (Fig.…”

Section: Pharmacological Treatmentmentioning

confidence: 99%

Aiming for a Better Understanding and Management of Cancer-Related Fatigue

Neefjes

Vorst

Blauwhoff‐Buskermolen

et al. 2013

The Oncologist

View full text Add to dashboard Cite

Cancer-related fatigue (CRF) is a serious symptom of patients with cancer and deteriorates their daily quality of life. Whereas fatigue is a common problem in the general population, with a prevalence of about 30%, up to 99% of patients with cancer have fatigue of more intense severity. CRF is directly related to the biology of cancer, but it can also be caused by anticancer treatment. We reviewed current evidence about the potential pathophysiological mechanisms causing CRF. Clinical methods to determine the presence and severity of CRF and potential treatment options to reduce CRF will be discussed. After reading this review, the reader will have knowledge of the current understanding of CRF and will be able to give evidence-based advice to patients with CRF. The Oncologist 2013;18:1135-1143Implications for Practice: Cancer-related fatigue (CRF) is a common problem in patients with cancer and has a major impact on quality of life. The causes of CRF are multifactorial and not fully understood. To get a better insight into the underlying mechanisms and the potential treatment possibilities of CRF, we provide an overview of currently available literature on this subject. Because current treatment options other than antitumor therapy for some of the patients are scarce and only directed at symptoms, further investigation of CRF is warranted to develop rational treatment options.

show abstract

“…Además dentro de los EC con pacientes oncológicos, la mayoría están referidos a diferentes tipos de tumor y con diferentes tratamientos, o en diferentes estadios 4,15,16,21 , donde se encuentra mayor alivio del dolor con metilfenidato en estadios más avanzados o mayor fatiga basal), motivos que puede limitar la interpretación de resultados comparables sobre el beneficio del metilfenidato sobre placebo de los EC estudiados.…”

Section: Tabla 2 Cuadro Resumen De Efectos Secundariosunclassified

Use of methylphenidate in palliative patients with asthenia: a review

Saralegui

Palácio

Royo

2013

Anales Sis San Navarra

View full text Add to dashboard Cite

La astenia o fatiga es uno de los síntomas más frecuentes en el paciente paliativo. Uno de los tratamientos, actualmente en evaluación, para combatir la misma es el metilfenidato. Este hecho, nos llevó a realizar una revisión de la bibliografía publicada hasta la fecha sobre su manejo, hallando al metilfenidato como un fármaco seguro que, globalmente, puede reducir la fatiga en el paciente paliativo, con un perfil de efectos secundarios tolerable. ABsTrACTAsthenia (or fatigue) is one of the most common symptoms in palliative patients. Methylphenidate is currently being assessed for treating this condition. A review of related literature published to date was performed, revealing methylphenidate to be a safe drug which could decrease fatigue in palliative patients with a tolerable side-effects profile

show abstract

Effect of methylphenidate on fatigue in women with recurrent gynecologic cancer

Abstract: This study provides support for the use of a psychostimulant to treat fatigue in women who have recurrent gynecologic cancer. It is particularly relevant for these patients with incurable disease who are facing the end of life.

Cited by 21 publications

References 17 publications

Practical Use and Risk of Modafinil, a Novel Waking Drug

Practical Use and Risk of Modafinil, a Novel Waking Drug

Aiming for a Better Understanding and Management of Cancer-Related Fatigue

Use of methylphenidate in palliative patients with asthenia: a review

Contact Info

Product

Resources

About